12th European Academy of Neurology Congress 2026

Persistence rates for CGRP mAb therapy in both adolescents and adults with high burden migraine in the German Pain e-Registry are higher than those recorded with older oral preventive agents. In 422 adolescents aged 12-17 years with ≥1 documented 6-month episode of high-evidence conventional oral preventives (HECP) and ≥1 subsequent CGRP mAb, 6-month persistence was 30.6% with HECP …

Further data from the ECLIPSE trial of atogepant in acute migraine treatment have shown consistent symptom relief across multiple migraine attacks.1-3 Pain relief and absence of most bothersome symptom (MBS), photophobia, phonophobia and nausea reported with atogepant in initial, ‘first attack’ data from the ECLIPSE  study, have proved consistent across three subsequent attacks. In addition, …

A significant majority of patients with migraine recognise premonitory symptoms (PreS), and more than half of those who respond to CGRP mAbs continue to experience PreS without headache. These were the key findings from a service evaluation by a major London headache centre in 223 patients (median age 48 years; 82% female). Sixty two per cent had chronic migraine, 29% had episodic migraine, …

Approximately one in 10 patients with migraine who were treated at a headache centre in Japan were able to ‘graduate’ from CGRP mAb therapy – discontinue treatment with substantial improvement – and those with fewest monthly migraine days (MMDs) at baseline, and absence of medication overuse headache (MOH), were most likely to succeed. These findings emerged from a retrospective …

Long term triple preventive therapy with botulinum toxinA (BoNT-A), fremanezumab and add-on atogepant can significantly reduce migraine frequency and improve disability scores in patients with refractory chronic migraine (CM), according to results of a 52-week, single centre case series. In 14 patients, sequential treatment with BoNT-A, fremanezumab and then add-on atogepant progressively decreased monthly headache …

Pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38) is measurable in tear fluid, indicating its potential as a biomarker reflecting migraine-specific mechanisms and supporting PACAP as an emerging target for novel therapies, suggest Italian researchers. In a cross-sectional study in 26 patients with migraine and 12 healthy controls (HCs), tear fluid was collected with Schirmer strips, and ELISA …